Bronstein, Gewirtz & Grossman, LLC filed a class-action lawsuit against ImmunityBio, Inc. The suit represents investors who purchased securities between January 19, 2026, and March 24, 2026.
The complaint alleges the company and its executives issued false and misleading statements. These statements reportedly overstated the capabilities of the cancer drug Anktiva.
The filing follows a March 2026 FDA warning letter regarding the company's promotional materials. Investors must petition for lead plaintiff status by May 26, 2026.